Summary
The NABUCCO trial investigated neoadjuvant combination checkpoint inhibitor therapy (ipilimumab plus nivolumab) in patients with locoregionally advanced urothelial cancer prior to radical cystoprostatectomy. As suggested by the trial design, the study assessed both immunological changes and clinical outcomes to evaluate the efficacy and safety profile of this dual-checkpoint approach in this patient population.
UK applicability
Findings may be applicable to UK oncology practice if the trial demonstrates efficacy, as NHS England includes checkpoint inhibitors in advanced urothelial cancer pathways; however, applicability depends on the specific patient populations studied and whether results align with existing UK treatment guidelines.
Key measures
Pathological response rates, immune cell infiltration, T cell activation markers, adverse events, surgical outcomes
Outcomes reported
The study evaluated immune responses and pathological outcomes in patients with locoregionally advanced urothelial cancer treated with preoperative ipilimumab and nivolumab before surgical resection. Clinical efficacy, immunological markers, and safety were assessed.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.